铂类耐药-话题@MedSci

#铂类耐药#

9篇内容 | 269人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1814991, encodeId=a1e01814991f3, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=293025, objectId=724d293025d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=724d293025d7, replyNumber=0, likeNumber=37, createdTime=2022-12-10, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=724d293025d7, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=724d293025d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814992, encodeId=e5221814992a0, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案, objectType=article, longId=294001, objectId=19182940012d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19182940012d, replyNumber=0, likeNumber=40, createdTime=2022-06-06, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19182940012d, moduleTitle=J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19182940012d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814990, encodeId=d11118149903f, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=212816, objectId=bee72128164e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee72128164e, replyNumber=0, likeNumber=47, createdTime=2022-03-30, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee72128164e, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee72128164e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814989, encodeId=305118149893a, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌, objectType=article, longId=154015, objectId=f65015401548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f65015401548, replyNumber=0, likeNumber=46, createdTime=2019-09-10, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f65015401548, moduleTitle=CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f65015401548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814988, encodeId=65dd181498807, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, objectType=article, longId=139686, objectId=ff45139686f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ff45139686f9, replyNumber=0, likeNumber=53, createdTime=2018-12-17, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ff45139686f9, moduleTitle=CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ff45139686f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814987, encodeId=0b66181498eab, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=依维莫司维持治疗原发性铂类耐药卵巢透明细胞癌一例, objectType=article, longId=124873, objectId=cba21248e361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cba21248e361, replyNumber=0, likeNumber=54, createdTime=2018-11-01, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cba21248e361, moduleTitle=依维莫司维持治疗原发性铂类耐药卵巢透明细胞癌一例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cba21248e361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814986, encodeId=cfab1814986cb, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, objectType=article, longId=103156, objectId=d8d010315642, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d010315642, replyNumber=0, likeNumber=45, createdTime=2018-05-08, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d010315642, moduleTitle=Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d010315642)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814985, encodeId=70f91814985af, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=Oncologist:哪些铂类耐药或抵抗的卵巢癌不该化疗？, objectType=article, longId=101930, objectId=d78d10193061, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d78d10193061, replyNumber=0, likeNumber=41, createdTime=2017-12-01, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d78d10193061, moduleTitle=Oncologist:哪些铂类耐药或抵抗的卵巢癌不该化疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d78d10193061)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814984, encodeId=7ed518149840d, content=<a href='/topic/show?id=85df9659123' target=_blank style='color:#2F92EE;'>#铂类耐药#</a>, objectTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, objectType=article, longId=38954, objectId=3ffd3895492, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ffd3895492, replyNumber=0, likeNumber=40, createdTime=2014-08-23, rootId=0, userName=yangfl06, userId=1c2e485, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ffd3895492, moduleTitle=阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ffd3895492)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

铂类耐药

2020-05-29

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-12-10

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

J Immunother Cancer：复肿吴小华教授团队研究表明卡瑞利珠单抗联合法米替尼（famitinib）可作为铂类耐药复发卵巢癌治疗有效方案

2022-06-06

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-03-30

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

CLIN CANCER RES：Binimetinib联合紫杉醇治疗铂类耐药卵巢癌

2019-09-10

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

CLIN CANCER RES：Guadecitabine联合卡铂治疗铂类耐药复发卵巢癌

2018-12-17

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

依维莫司维持治疗原发性铂类耐药卵巢透明细胞癌一例

2018-11-01

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

Int J GynecolCancer：阿那曲唑治疗雌激素受体或孕激素受体阳性的铂类耐药的复发性卵巢癌患者的二期临床试验

2018-05-08

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

Oncologist:哪些铂类耐药或抵抗的卵巢癌不该化疗？

2017-12-01

yangfl06 (审核中...)

前往app查看评论内容

#铂类耐药#

阿瓦斯汀铂类耐药复发性卵巢癌新适应症获欧盟批准

2014-08-23

科室
- - 订阅+
  - 更多科室
工具
服务